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Introduction
Cancer patients have a high risk of venous thromboembolism
(VTE), sometimes being the first manifestation of a so-far
hidden malignancy. Mechanisms leading to thrombus forma-
tion in cancer patients are incompletely understood, although







Abstract Despite the growing interest and improved knowledge about venous thromboembo-
lism in cancer patients in the last years, there are still many unsolved issues. Due to the
limitations of the available literature, evidence-based clinical practice guidelines are
not able to give solid recommendations for challenging scenarios often present in the
setting of cancer-associated thrombosis (CAT). A multidisciplinary expert panel from
three scientific societies—Spanish Society of Internal Medicine (SEMI), Spanish Society
of Medical Oncology (SEOM), and Spanish Society Thrombosis and Haemostasis (SETH)
—agreed on 12 controversial questions regarding prevention and management of CAT,
which were thoroughly reviewed to provide further guidance. The suggestions
presented herein may facilitate clinical decisions in specific complex circumstances,
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itself. Themanagement of cancer-associated thrombosis (CAT)
frequently represents a challenge for clinicians due to very
poor or lack of evidence regarding common daily practice
scenarios that have also been poorly addressed by most
currently available evidence-based guidelines.1–5
This work arises from a joint initiative of amultidisciplinary
panel of experts under the auspice of the Spanish Society of
InternalMedicine (SEMI), Spanish Society ofMedical Oncology
(SEOM), and Spanish Society of Thrombosis and Haemostasis
(SETH), who leaned on literature to reach consensus on con-
troversial issues aimed to guide clinicians to manage complex,
albeit not uncommon, situations related to CAT, until further
evidence supporting or discouraging the proposed recommen-
dations becomes available. Our aim is not to produce another
evidence-based guideline on the field but to provide useful
advice for scenarios that clinicians involved in CAT have to face
without the support of unequivocal strong evidence-based
recommendations.Dueto thespecificwordingof thequestions,
most of themhave not been previously approached elsewhere.
Methods
In the first meeting, the whole panel agreed on 12 specific
controversial questions that were to be addressed. The topics
were identified by a recent Delphi study and completed by
ownexperience.6 The questionswere distributed among four
teams of three experts, including onemember of each society
(i.e., three questions per team). For every topic, the available
literature (from previous guidelines to small studies) was
reviewed and an initial consensus was reached inside each
working team leading to a proposal of suggestions for the
assigned questions. In the final meeting, the whole panel
discussed all the proposals until agreement was reached. An
executive summary is presented in ►Table 1, also including
the most relevant literature for each topic.
Results
Question 1: In Ambulatory Cancer Patients, Should the
Thrombotic Risk Be Evaluated Using a Risk Score to
Decide on the Use of Antithrombotic Prophylaxis?
Background
To date, the only validated prediction model of CAT is the
Khorana risk score.7However, in recent years several studies
in different types of cancer suggest that this should not be the
only tool to select candidate patients for antithrombotic
prophylaxis in the outpatient setting8–11:
• A recent assessment questions the usefulness of the
Khorana score, Vienna-CATS predictionmodel, PROTECHT
score, or CONKO score for this aim.12
• Two recent models, COMPASS13 and ONKOTEV,14 which
rely on clinical parameters only, seem to overcome the
predictive ability of the Khorana score. At 6 months, the
area under the curve (AUC) of receiving operating
Table 1 Summary of recommendations
Question Background Suggestions
Prophylaxis
1. In ambulatory cancer patients, should
thrombotic risk be evaluated using a risk
score to decide on the use of antithrom-
botic prophylaxis?
• The accuracy of Khorana, Vienna-CATS,
PROTECHT, or CONKO scores is lim-
ited.10–12
• COMPASS, ONKOTEV, and ONCO-
THROMB require validation.13,14,16
• Some tumor-specific scores have been
recently developed showing promising
results.17,18
• Thrombotic risk should be evaluated,
but not only by using the Khorana’s risk
score.
• Attention has to be paid to new scores
with improved predictive ability,
although validation is required.
2. In cancer patients who are hospitalized
for an acute medical illness, when is phar-
macological antithrombotic prophylaxis
contraindicated?
• Hospitalized cancer patients have a high
risk of VTE and, whenever possible,
preventive measures have to be imple-
mented.1–5
• However, studies that weigh the risk–
benefit balance in this specific popula-
tion are lacking.
• Therefore, safety must be specially
considered in the clinical decision-mak-
ing process.
• Absolute contraindications of pharma-
cological prophylaxis:
- Recent bleeding in CNS; active major
bleeding; platelet count <20  109/L.
• Relative contraindications:
- Relevant chronic bleeding (duration
>48 h); initial period of postneurosur-
gery; spinal or intracranial lesions;
platelet count 20–50  109/L; drug-
related platelet dysfunction or uremia;
underlying coagulopathy.
• Wait 12 h after last prophylactic-dose
LMWH administration for lumbar punc-
ture or spinal anesthesia.
• In case of contraindication, apply phy-
sical antithrombotic measures.
• Thromboprophylaxis is not required in
cancer patients hospitalized exclusively
to receive oncologic treatment (except
in case of immobilization).
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3. Must LMWH dose be modified in cancer
patients with acute VTE treated with anti-
angiogenic drugs?
• Most clinical trials assessing antiangio-
genic drugs excluded anticoagulated
patients.
• Indirect information can be obtained
from some bevacizumab studies.25–33
• In general, the LMWH dose should not
be modified in patients developing a
VTE event while on antiangiogenic
treatment.
• Special caution is required in case of CNS
involvement.
• Resumption of the antiangiogenic ther-
apy (if indicated) should be delayed at
least 2 wk after starting LMWH.
4. In patients with CAT requiring surgery or
invasive procedure, when should the pla-
cement of an inferior vena cava filter be
considered?
• Results from studies on the use of IVCF in
cancer patients with VTE are controver-
sial.34–40
• Consensus exists on its use in patients
with PE or DVT when ACG is contra-
indicated, especially in the first weeks
after VTE.41–44
• Concern about early and delayed
adverse effects associated with IVCF is
increasingly growing.41,44–47
• Use of IVCF is suggested in cancer
patients with acute lower limb proximal
DVT/PE, who require a procedure that
contraindicates ACG, particularly in the
first 2–4 wk after the thrombotic epi-
sode.
• After the first 2–4 wk, use IVCF only if
proximal DVT persists.
• While IVCF remains inserted, if possible,
administer LMWH at least at prophylac-
tic doses.
• Remove IVCF and restart full ACG as soon
as the cause that led to placement is
resolved.
Long-term treatment
5. In patients with CAT that require
extended anticoagulant therapy beyond 6
mo, what is the optimal dose if LMWH is
maintained?
• Guidelines recommend maintaining
ACG beyond 6 mo in cases of active
cancer and/or ongoing chemotherapy,
although optimal drugs and doses are
not specified.44,48
• Evidence on LMWH doses to use beyond
6 mo is scarce.
• An observational49 and two single-arm
prospective studies, DALTECAN50 and
TICAT (451), provide useful information.
• DOACs may be an alternative for
selected patients with low risk of gas-
trointestinal bleeding and drug
interactions.54,56
• Decide dose according to characteristics
of patient, of the disease and its treat-
ment, and of the VTE event:
- Patient
▪ Full doses: obesity; thrombophilia;
immobilization; venous insuffi-
ciency; varicose veins and low
bleeding risk.
▪ Intermediate/prophylactic doses:
renal failure or thrombocytopenia,
or/and high bleeding risk.
- Tumor
▪ Full doses: metastatic disease or
locoregional disease with vessel
compression; tumors with high
thrombotic risk.
▪ Intermediate/prophylactic doses:
tumors with lower thrombotic risk.
- VTE event
▪ Full doses: life-threatening symp-
tomatic PE, recurrent VTE, post-
thrombotic syndrome.
▪ Intermediate/prophylactic doses:
incidental PE; isolated LL DVT; CVC-
associated thrombosis; recurrent
SVT.
▪ Dose increased by 25%: VTE recur-
rence in spite of appropriate
LMWH.
6. Should anticoagulant treatment be
prolonged beyond 3–6 mo in cancer
patients with CVC-DVT, when the central
venous line is maintained? Is LMWH pro-
phylaxis indicated in patients with previous
CVC-DVT if a new CVC has to be inserted?
• Current recommendations are not uni-
form across different guidelines and not
supported by evidence of sufficient
quality.43,44,57–59
• If the CVC is maintained beyond the first
3–6 mo of anticoagulation after a CVC-
DVT, the scenario could be considered
as a VTE secondary to a persistent risk
factor.
• After 3–6 mo, if bleeding risk is not high,
prolong ACG using intermediate or pro-
phylactic doses of LMWH until CVC
removal.
• If a new CVC is inserted in a patient with
previous history of CVC-DVT, use pro-
phylaxis with LMWH for 30 d. Consider
longer periods depending on bleeding
risk and patient’s preferences.
(Continued)
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Treatment of VTE in complex scenarios
7. How should CAT be treated in cases of
primary or secondary central nervous sys-
tem involvement?
• Anticoagulation is effective, and usually
well tolerated, in patients with glio-
mas62 or cerebral metastases.63 Some
data favor treatment modifications
under certain circumstances.
• Brainstem hemorrhages are particularly
serious.
• In general, use LMWH according to
standard guidelines.
• The following exceptions are made:
- In secondary CNS involvement due to
melanoma or kidney cancer, if VTE is not
severe, reduce LMWH dose by 25–50%.
- In patients with brainstem glioma, initi-
ally reduce LMWH dose by 25–50%, until
local control of the disease is achieved.
8. Should incidental splanchnic venous
thrombosis be treated?
• In a prospective registry of splanchnic
VT, not limited to cancer patients,
recurrences were more frequent in male
patients with incidental thrombosis and
shorter time on ACG.66,67
• While on anticoagulant treatment, in
patients with incidentally diagnosed
splanchnic VT, the rate of major bleed-
ing did not exceed that of recurrent
thrombosis, although specific results in
cancer patients are unknown.
• Individualization is suggested according
to chronic/nonchronic nature of
thrombus.42,68
• Start ACG treatment unless there is a
formal contraindication.
• Individualize in case of:
- Data suggestive of chronic thrombosis.
- Isolated thrombosis of intrahepatic
portal segmental branch.
• ACG should be maintained for at least 3
mo.
9. In cancer patients with acute VTE, what
platelet count threshold would imply
modifications in the LMWH dose? Can
platelet transfusions avoid LMWH dose
reductions?
• Full-dose ACG is accepted with platelet
counts >50  109/L. Controversy arises
with lower values.
• There is reticence about recommenda-
tion of transfusing platelets to reach
>50  109/L to maintain therapeutic
LMWH doses [ISTH and Canadian Con-
sensus41,69,74]: it is complex and is
associated with risk of adverse
effects.70,71
• Others support dynamic strategies of
ACG dose reduction,73 or platelet
transfusion with lower thresholds
(<20  109/L).71
• With counts 50  109/L, maintain full
doses of LMWH.
• With counts between 20 and 50  109/
L, reduce LMWH 50%.
• With counts 20  109/L
- If >30 d since VTE diagnosis, withhold
ACG.
- If <30 d since VTE diagnosis, transfuse
platelets to maintain counts
>20  109/L, and use intermediate
LMWH doses.
• Consider IVCF in the acute phase of VTE
(especially when thrombocytopenia is
thought to last >5 d) in:
- Patients with counts 20  109/L.
- Patients with counts 20–50  109/L
and low cardiopulmonary reserve.
10. In patients with acute CAT requiring
anticoagulant treatment and who were
under antiplatelet therapy, when should
the latter be maintained?
• ACGwith VKA prevents coronary disease
progression, and ischemic stroke in AF
patients.76
• The combined use of antiplatelet drugs
with ACG treatment does not always
improve ischemic events prevention and
increases hemorrhagic risk.77,78
• The use of VKA together with two anti-
platelet drugs involves a highhemorrhagic
risk, but may be justified for short periods
in situations of high thrombotic risk.79
• In patients with thrombosis associated
with a MPN, the benefit of combined
aspirin plus ACG is probably overweighed
by the increased risk of bleeding.81–83
• In cancer patients on ACG treatment for
VTE, maintain antiplatelet drugs only in
exceptional situations of markedly ele-
vated risk of coronary events.
•Maintenance of antiplatelet treatment in
patients who are going to start antic-
oagulant therapy for CAT is justified in
case of recent (<1 y) ACS event or
placement of a coronary stent.
• In patients with acute CAT carrying
stents in other vascular beds, mainte-
nance of antiplatelet treatment while on
anticoagulant therapy should be
decided in a case-by-case basis.
Laboratory
11. In cancer patients treated with LMWH,
when should anti-factor Xa activity be
monitored?
• In studies with LMWH for the treatment
of CAT, no relevant accumulation over
time was observed.55,84,85
• However, there are situations where phar-
macokinetics of LMWHmay be affected.87
• Thrombocytopenia does not alter LMWH
pharmacokinetics.
• In patients with CAT, routine monitoring
of anti-Xa activity is not required.
• In cases of creatinine clearance
<30mL/min, extreme body weight, or
pregnancy, LMWH dose adjustment
according to peak anti-Xa activity is
suggested.
TH Open Vol. 2 No. 4/2018



















































characteristics of the COMPASS risk assessment model
was 0.85. The ONKO-TEV score showed an AUC at
3 months of 71.9 versus 57.9% with the Khorana score.
However, validation is still required.
• The addition of some biomarkers such as D-dimer or
genomic risk profiles may help improve the usefulness
of VTE risk scores.15,16
• A different strategy, based on tumor-specific assessment
models, has been developed. The Throly score, developed
for patients with lymphomas, showed high negative pre-
dictive value (NPV; 97%), although the positive predictive
value (PPV) was 15%. Another new risk model for predic-
tion of VTE in gynecological cancer patients has also
shown promising results.17,18
Currently, routine thromboprophylaxis in ambulatory
cancer patients is not recommended. Better tools to stratify
VTE risk are needed to favor a primary prevention strategy in
ambulatory cancer patients.
Suggestions
• Assessment of thrombotic risk in cancer patients on
ambulatory treatment is suggested, with the purpose of
identifying those who would, theoretically, benefit more
from antithrombotic prophylaxis.
• Although Khorana’s risk score is the only validated predic-
tionmodel, it should not be the only tool used to select the
patients who will receive ambulatory antithrombotic pro-
phylaxis. Bleeding risk factors also have to be considered.
• New predictive models including biomarkers such as D-
dimer or genomic risk profile, or tumor-specific scores,
may help improve risk stratification.
Question 2: In Cancer Patients Who Are Hospitalized
for an Acute Medical Illness, When Is Pharmacological
Antithrombotic Prophylaxis Contraindicated?
Background
Current guidelines agree that cancer patients who are hos-
pitalized for any complication related to their clinical con-
dition are at very high VTE risk, recommending
pharmacologic prophylaxis with low-molecular-weight
heparin (LMWH), unless contraindicated.1–5 However, stu-
dies that specifically address the risk–benefit of thrombo-
prophylaxis in cancer inpatients are lacking. In fact,
recommendations are based on the results of trials whose
cohorts consisted of heterogeneous groups of medical
patients, among which cancer patients were underrepre-
sented (5–15%).19–23 A recent meta-analysis restricted to the
cancer subgroup of the aforementioned studies did not
confirm a positive effect of thromboprophylaxis.24
On the other hand, cancer patients also exhibit an
increased bleeding tendency and are considered as a high-
risk population for hemorrhages. Therefore, a careful bene-
fit–risk balance for each individual patient is advisable.
Although validated tools to assess bleeding risk in cancer
patients are lacking, several circumstances imply a contra-
indication for pharmacologic thromboprophylaxis.
Suggestions
• Settings where primary thromboprophylaxis with LMWH
is contraindicated for cancer inpatients:
– Absolute contraindications:
▪ Recent bleeding in the central nervous system.
▪ Active major bleeding.
▪ Thrombocytopenia <20  109/L.
Table 1 (Continued)
Question Background Suggestions
• An association between anti-Xa activity and
either clinical efficacy or hemorrhagic risk
has not been demonstrated.89
• Monitoring anti-Xa in patients with
thrombocytopenia or with other
hemorrhagic risk factors is not sug-
gested. The LMWH dose should not rely
on this variable.
• Monitoring anti-Xa activity is not sug-
gested for prophylactic doses of LMWH.
12. Should thrombophilia study be per-
formed in patients with CAT?
• Thrombophilic abnormalities have little
influence on clinical decisions on ACG
for VTE.43,91,92
• In the cancer setting, initial ACG treat-
ment for CAT is similar in patients with
thrombophilia, and ACG duration is
mainly influenced by cancer
status.42–44,91
• In patients with CAT, do not routinely
investigate the presence of
thrombophilia.
Abbreviations: ACG, anticoagulation/anticoagulant; ACS, acute coronary syndrome; AF, atrial fibrillation; anti-Xa, anti-factor Xa; CNS, central nervous
system;CAT, cancer-associated thrombosis; CVC, central venous catheter; CVC-DVT, deepvenous thrombosis associatedwith central venous catheter; DVT,
deep venous thrombosis; ISTH, International Society onThrombosis and Haemostasis; IVCF, inferior vena cava filter; LL, lower limbs; LMWH, low-molecular-
weight heparin(s); MPN, myeloproliferative neoplasm; PE, pulmonary embolism; SEMI, Spanish Society of Internal Medicine; SEOM, Spanish Society of
Medical Oncology; SETH, Spanish Society of Thrombosis and Haemostasis; SVT, superficial vein thrombosis; VKA, vitamin K antagonists; VTE, venous
thromboembolic event/venous thromboembolism.
Notes: Twelve experts from the SETH, SEOM, and SEMI formed four teamsof three,which included onemember of each society. Each teamelaborated initial
consensus statements on three different questions. After a subsequent discussionwith theparticipation of thewhole panel of experts, a final consensuswas
reached for each one of the 12 proposed questions, all of which are controversial because of the scarce solid literature available about them.
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▪ Clinically relevant chronic bleeding, lasting for
more than 48 hours.
▪ Initial period of postneurosurgery (48–72 hours).
▪Highbleeding risk–associated spinal or intracranial
lesions (e.g., melanoma or kidney metastases).
▪ High risk of falls.
▪ Thrombocytopenia 20  109 to 50  109/L.
▪ Severe platelet dysfunction.
▪ Underlying coagulopathy.
▪ Lumbar puncture or spinal anesthesia (proce-
dures should be delayed 12 hours after last
prophylactic LMWH dose).
• When pharmacological thromboprophylaxis is contrain-
dicated, alternative use of mechanical measures is
suggested.
• Thromboprophylaxis with LMWH is not necessary in
patients admitted to hospital for scheduled oncological
treatment who are not immobilized.
Question 3: Must the LMWH Dose Be Modified in
Cancer Patients with Acute VTE Receiving
Antiangiogenic Drugs?
Background
Patients on anticoagulant therapy were explicitly excluded
from most clinical studies with antiangiogenic drugs.25,26
Furthermore, in those studies that allowed participation of
anticoagulated patients, vitamin K antagonists (VKA) instead
of LMWH (drug of choice for CAT treatment) were mostly
used. Certain evidence arises from several clinical trials
evaluating bevacizumab:
• Observational prospective or phase IV studies.
The BEAT27 and the BRITE28 studies provided comparative
analyses on the incidence of severe bleeding (SB [grades 3–
5]) between anticoagulated and non-anticoagulated bevaci-
zumab-treated patients. Both studies showed higher SB rates
among anticoagulated patients (4.3 vs. 2.4% in BEAT and 6.0
vs. 2.2% in BRITE, respectively). In contrast, in the SAIL study
the SB rate in patients under anticoagulant therapy was null,
compared with 4% in the overall cohort.29
• Clinical trials allowing anticoagulant therapy.
In the pivotal trial, the proportion of patients who main-
tained the study treatment after suffering a VTE event and
startinganticoagulant therapywas6.5% in thebevacizumabarm
and3.4% in the placebo arm.26 SB episodeswere experienced by
3.8 and6.7% of those patients, respectively.30On the contrary, in
the AVADO study, the incidence of SB among anticoagulated
bevacizumab-treated patients was 5% compared with 0% in
anticoagulated placebo-treated patients, and 1.2% in the bev-
acizumab group that did not receive anticoagulants.31
• Systematic reviews.
Data from 3,201 patients were collected.32 Patients were
allowed to continuewith the studymedication after an acute
VTE event if the following criteria were fulfilled: absence of
active bleeding, maintenance of stable anticoagulation for at
least 2 weeks, and, in two of the three studies, absence of
major vessel invasion. The SB rates, obtained from 194
anticoagulated patients, were similar in those treated with
either bevacizumab or placebo (4.1 vs. 4.2%, respectively).
• Meta-analysis.
Finally, a meta-analysis including 10 studies and 6,055
bevacizumab-treated patients found that 10.5% of thosewho
suffered a VTE and started anticoagulant therapy did not
discontinue the antiangiogenic treatment.33 In this sub-
group, the bleeding ratewas 1.9% (SB in 0.2% of cases), versus
1.2% among patients who did not require anticoagulant
treatment.
Suggestions
• In the absence of bleeding, a reduction of the LMWH dose
to be administered to a patient developing an acute VTE
event while on antiangiogenic treatment is not suggested.
Special caution is required in patients with central ner-
vous system involvement.
• Resumption of the antiangiogenic therapy, after starting
anticoagulant therapy for an acute VTE event, should be
delayed for a reasonable period of 2 weeks to check the
absence of any bleeding complication before adding any
further risk factor. In case of life-threatening VTE, resump-
tion of the antiangiogenic therapy is not recommended.
Question 4: In Patients with CAT Requiring Surgery or
an Invasive Procedure, When Should the Placement of
an Inferior Vena Cava Filter Be Considered?
Background
The evidence supporting the use of inferior vena cava filters
(IVCFs) in cancer patients is scarce. While some studies
suggested that IVCFs are safe and effective, others found an
increased risk of recurrent deep venous thrombosis (DVT;
indeed, the cancer-related hypercoagulability is not cor-
rected by the IVCF), as well as no benefit regarding pulmon-
ary embolism (PE) incidence or short-term mortality.34–40
Nevertheless, most guidelines recommend the use of IVCF in
cancer patients with proximal acute DVT or PE when antic-
oagulant therapy is contraindicated.41–44 Such is the case of
major surgery or invasive procedures. Lumbar puncture,
spinal anesthesia, or epidural catheter placement are con-
sidered as special procedures.42 The use of IVCF would be
particularly useful within the first 2 to 4 weeks after the
acute thrombotic event due to thehigh recurrence risk in that
particular period.45 The use of IVCF is not clearly supported
in other scenarios.45–47 Furthermore, other potential adverse
events associated with its use, such as placement or removal
complications, migration, breakage, or thrombosis of the
device, should be taken into account.41,44–47
Moreover, anticoagulation should be restarted, and the
IVCF removed, once the contingency that led to its placement
is resolved. The strategy of IVCF removal should be defined
prior to filter insertion.41,43–46
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• The use of a retrievable IVCF is suggested in cancer
patients with acute proximal lower limb DVT or PE who
require surgery or an invasive procedure that contra-
indicates anticoagulant therapy, particularly within the
first 2 to 4 weeks after diagnosis. After 4 weeks from the
diagnosis of the thrombotic episode, the placement of an
IVCF is suggested in case of persistent proximal DVT
(femoral or iliac veins).
• While the IVCF remains placed, the use of (at least)
prophylactic LMWH, if not contraindicated by the bleed-
ing risk, is suggested.
• Full anticoagulant therapy should be restarted and IVCF
removed as soon as the cause leading to the placement of
the filter is resolved.
Question 5: In Patients with CAT Who Require
Extended Anticoagulant Therapy beyond Six Months,
What Is the Optimal Dose if LMWH Is Maintained?
Background
After completing 6 months of anticoagulant therapy for CAT,
current clinical guidelines recommend to continue antic-
oagulation in case of active cancer and/or ongoing che-
motherapy due to the high risk of recurrent VTE. However,
since the observation period in available randomized trials
comparing VKA and LMWH in this setting lasted 6 months,
the drug/dose of choice for extended therapy is a matter of
debate.44,48
Useful data are provided by a subgroup analysis of an
observational study,49 and two single-armprospective studies
designed to evaluate LMWH safety over a 12-month period:
the DALTECAN study,50 in which dalteparin dose was reduced
after the first month of treatment, and the TICAT study,51 in
which tinzaparin was used at full dose throughout the study.
Until stronger evidence becomes available, the dose of
LMWH for extended therapy beyond 6 months should be
tailored considering several issues: severity of VTE, cancer
type and extension, ongoing anticancer therapies, bleeding
risk, and patients’ characteristics and preferences, which may
change over time.52,53 Indeed, intrinsic differences in the
dosing of the various LMWH must be taken into account (as
mentionedearlier, the standard therapeutic dose ofdalteparin
after the first month of treatment is 150 IU/Kg instead of 200
IU/Kg,while for theothermolecules thefull dose ismaintained
during the 6-month anticoagulation period).
Other options for extended therapy are VKA (although
maintaining therapeutic INR ranges may be difficult in
cancer patients under active antineoplastic therapy) and
direct oral anticoagulants (DOACs). Very recently, two ran-
domized clinical trials in patients with CAT have compared
the efficacy and safety of edoxaban and rivaroxaban, direct
factor Xa inhibitors, versus dalteparin using the CLOT trial
scheme (200 UI/kg/day the first month, 150 UI/kg/day after-
ward)54–56 for a minimum observation period of 6 months.
In the Hokusai-VTE cancer study, no significant differences
were observed in the rate of the primary composite endpoint
(recurrent VTE and/or major bleeding), albeit patients in the
edoxaban arm had a lower rate of VTE recurrence and a
higher rate of major bleeding, especially gastrointestinal
bleeding.54 Similarly, the 6-month cumulative VTE recur-
rence rate was higher with dalteparin compared with rivar-
oxaban, although major bleeding was increased in the
rivaroxaban arm.56 The results of other ongoing studies
may confirm a role of DOACs as an alternative for CAT
extended therapy. However, current restraints by health
authorities limit its use in patients with VTE in Spain and
other countries, making LMWH the drug of choice for
extended treatment of CAT.
Suggestions
• When LMWH treatment for CAT is to be prolonged beyond
6 months, the characteristics of each individual patient, of
the underlying malignancy and its treatment and of the
indexVTE, shouldbe considered todecide theoptimaldose.
►Table 2 summarizes useful criteria to guide decisions.
Question 6: Should Anticoagulant Treatment Be
Prolonged Beyond 3–6Months in Cancer Patients with
Catheter-Related DVT (CVC-DVT), When the Central
Venous Line Is Maintained? Is LMWH Prophylaxis
Indicated in Patients with previous CVC-DVT if a New
CVC Is Needed?
Background
Some guidelines have addressed the initial management of
central venous catheter (CVC)-DVT in cancer patients,
although the strength of the evidence is limited.43,44,57–59
In fact, the use of LMWH in this setting relies on general
clinical trials of CAT. In general, anticoagulation for a mini-
mum period of 3 months is recommended, even if the CVC is
removed earlier. However, the CVC can be kept in place as
long as it is functional, not infected, and DVT-related symp-
toms improve adequately.
In certain sense, if the CVC is maintained (or a new CVC is
placed) beyond thefirst 3 to 6months of anticoagulation for a
CVC-DVT episode, the scenario could be comparable to a
provoked VTEwith a persistent risk factor. Therefore, the risk
of recurrent thrombosis without anticoagulant treatment
would be relatively high. In a study from the RIETE registry,
the incidence of recurrent thrombosis after discontinuation
of anticoagulant therapy in patients with CVC-DVT was 3.4
events/100 patient-years, but the proportion of patients in
whom the central line remained inserted was not speci-
fied.60 Another retrospective study suggested that after
3 months of LMWH, anticoagulation can safely be discon-
tinued in patients with CVC-DVTwhen cancer is in remission
and catheter is removed.61 Two late recurrent VTE events
(lower limb DVT) were observed in 16 patients in whom the
central line was kept and continued anticoagulation beyond
3 months. In both cases, the patients were receiving only
prophylactic doses of LMWH. No recurrent upper extremity
DVT was observed in this group. Given the low number of
patients and events, no definite conclusions regarding the
optimal dose of LMWH for secondary prevention in this
scenario can be derived.
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• When the CVC is maintained after having completed 3 to
6months of LMWH treatment due to a CVC-DVT event in a
cancer patient, prolongation of LMWH therapy using
intermediate or prophylactic doses is suggested. Treat-
ment should be continued until CVC removal, as long as
patient’s bleeding risk is not high.
• In cancer patients with previous CVC-DVT history who
require a new CVC, LMWH prophylaxis for at least 30 days
after placement is suggested. Prophylaxis for a longer
period, as long as the CVC remains inserted, may be
considered, although patient’s bleeding risk and prefer-
ences should also be valued.
Question 7: How Should CAT Be Treated in Patients
with Primary or Secondary Central Nervous System
Involvement?
Background
Anticoagulation is effective, and usually well tolerated, in
patients with gliomas62 or cerebral metastases.63 Neverthe-
less, some data may favor treatment modifications under
certain circumstances:
• A retrospective study analyzed the outcomes of 364
patients with CAT, half of them with primary or meta-
static brain tumors, for a median time of 6 months.64
There were no differences between groups in the inci-
dence of VTE recurrence (11.0 vs. 13.5 cases per 100
patients-year, p ¼ 0.26) or major bleeding (8.9 vs. 6.0
cases per 100 patients-year, p ¼ 0.80).
• Another retrospective study included 293 patients with
cerebral metastases, 104 of who received therapeutic
doses of enoxaparin due to acute VTE.63 There were no
differences in the 1-year incidence of cerebral hemor-
rhage compared with non-anticoagulated patients (total
bleeding: 44 vs. 37%, respectively, p ¼ 0.13). The risk of
intracranial hemorrhage was fourfold higher for mela-
noma or kidney cancer when compared with lung cancer,
although the increased risk was not associated with
enoxaparin use.
• Ameta-analysis with 1,480 patients with central nervous
system (CNS) malignancies compared the risk of intra-
cranial hemorrhage between those who received antic-
oagulant therapy with LMWH or warfarin, and those who
were not treated with anticoagulant drugs.65 The odds
ratio (OR) of intracranial hemorrhage in anticoagulated
patients was 2.13 (95% confidence interval [CI]: 1.0–4.56).
The risk was not increased in patients with CNS metas-
tases (OR: 1.07, 95% CI: 0.61–1.88), in contrast to those
with cerebral glioma (OR: 3.75, 95% CI: 1.42–9.95). How-
ever, the higher incidence of intracranial bleeding did not
seem to be associated with LMWH use (OR: 0.75, 95% CI:
0.24–2.33).
Table 2 Criteria to decide LMWH dose when anticoagulant treatment for CAT is prolonged beyond the first 6 mo
Full-dose LMWHa Intermediate or prophylactic
LMWH dose
LMWH dose increased 25%
VTE event • Life-threatening
symptomatic PE
• Incidental PE
• Isolated lower limb DVT
• Catheter-associated thrombosis












Neoplasm • Metastatic disease
• Tumor vessel compression
• High thrombotic risk cancer:
lung, pancreas,
gastroesophageal
• Cancers with lower
thrombotic risk:
breast, prostate






• No bleeding history
High:
• Previous tumor bleeding
• Previous bleeding history due
to any other cause
• Treatment with
antiangiogenic drugs
• Concomitant treatment with
antiplatelet drugs
Abbreviations: CAT, cancer-associated thrombosis; DVT, deep venous thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism;
SVT, superficial vein thrombosis; VTE, venous thromboembolism.
aFor dalteparin, full doses after the first month of treatment, according to DALTECAN and CLOT studies, is 150 IU/kg/24 hours.47,52
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• Finally, since brainstem hemorrhages are particularly
serious, any condition involving such area should be
managed cautiously.
Suggestions
• In general, in the absence of other contraindications, in
patients with primary or secondary neoplastic involve-
ment of CNS, standard treatment of CAT with full-dose
LMWH according to guidelines is suggested. However, the
following exceptions may be considered:
– In patients with secondary CNS involvement from
melanoma or kidney cancer, and especially when the
VTE event is not severe, a 25 to 50% reduction of the
LMWH dose could be considered.
– In cases of glioma in the brainstem, a 25 to 50%
reduction in LMWH dose is suggested. If disease con-
trol with local treatment is achieved, a subsequent
LMWH dose increase may be weighed.
Question 8: Should Incidental Splanchnic Venous
Thrombosis Be Treated?
Background
The most relevant information comes from a recent interna-
tional registry promoted by the ISTH, although the study was
not limited to cancer patients.66,67 A total of 604 splanchnic
venous thromboses (VTs), 177 (30%) of them incidental, were
consecutively included. Sixty-two of 177 (35%) incidental
splanchnic VTs were associated with nonhematologic cancer.
In this latter group, onemajorbleedingevent (1.2 casesper100
patients-year) and seven thrombotic recurrences (8.1 cases
per 100 patients-year) were observed during follow-up.67
However, additional analyses may be useful for the decision-
making process:
• The probability of being administered anticoagulant
treatment was lower in both, patients with cancer and
patients with incidental thrombosis.67
• Treatments given to patients with incidental splanchnic VT
were markedly heterogeneous regarding drug and dura-
tion. Patterns ranged from 6months with parenteral antic-
oagulants, especially LMWH, to 24monthswithoral VKA.67
• Patients with thrombocytopenia (platelet count
100  109/L) were less prone to receive anticoagulant
treatment, and showed the highest rate of major bleed-
ing.67 A thrombotic recurrent event was more frequently
seen in male patients with incidental thrombosis and
shorter duration of the anticoagulant therapy.66
• Regardless of cancer, the rate of recurrences during antic-
oagulant treatment was similar in patients with sympto-
matic or incidental splanchnic VT.67
• While on anticoagulant treatment, in patients with inci-
dentally diagnosed splanchnic VT, the rate of major bleed-
ing did not exceed that of recurrent thrombosis, although
specific results in cancer patients are unknown.67
In another recent study from the RIETE group including
521 patients with splanchnic VT, 309 (59%) incidental, most
of them received anticoagulant therapy.68 Compared with
patients with symptomatic splanchnic VT, those with inci-
dental splanchnic VT had a nonsignificantly higher risk of
symptomatic VTE recurrence (hazard ratio [HR]: 2.04; 95%
CI: 0.71–5.88) and a similar risk of major bleeding (HR: 1.12;
95% CI: 0.47–2.63). Active cancer was associated with an
increased risk of recurrence (HR: 3.06; 95% CI: 1.14–8.17).
Although the quality of the evidence is low, international
guidelines suggest that in cancer patients with incidental
splanchnic VT, anticoagulant treatment should be consid-
ered in a case-by-case basis, taking into account clinical data
suggestive of chronic thrombus, such as collateral circulation
or portal cavernomatosis.42,58 No recommendation about
the need of an upper gastrointestinal endoscopy to look for
esophageal varices that could be treated before starting
anticoagulant therapy is made. There are no specific recom-
mendations according to the splanchnic vein involved either.
Nevertheless, anticoagulant therapy seems more warranted
in patients with portal thrombosis candidates for liver
transplantation, or in those with superior mesenteric vein
thrombosis involving a large intestinal surface area.
Suggestions
• Unless contraindicated, in cancer patients diagnosedwith
incidental splanchnic VT, starting anticoagulant treat-
ment is suggested.
• Treatmentshouldbe individualized incaseswithclinicaldata
suggesting chronic thrombosis, as well as in cases of isolated
thrombosis of an intrahepatic portal segmental branch.
• Anticoagulant treatment should bemaintained for at least
3 months.
Question 9: In Cancer Patients with Acute VTE, What
Platelet Count Threshold Would Imply Modifications
in the LMWH Dose? Can Platelet Transfusions Avoid
LMWH Dose Reductions?
Background
Full-dose anticoagulation with platelet counts higher than
50  109/L is universally accepted, also in the context of CAT.
However, management with lower counts is controversial.
Both, the ISTH in 2013 and the 2015 Canadian Consensus
Guidelines recommended the following41,69:
• For VTE diagnosed more than 30 days ago, anticoagulant
dose should be reduced in case of platelet counts lower
than 50  109/L.
• In the acute phase of VTE (i.e., thefirst 30 days since onset),
transfuse platelets to reach counts higher than 50  109/L,
and anticoagulation should be kept at full therapeutic
doses. This recommendation is based on the higher risk
of recurrence during the first month after VTE diagnosis.
However, there are some concerns regarding this last
recommendation70,71:
• First, sustaining an intensive platelet transfusion program
to reach and maintain the threshold of 50  109/L is not
easy and in many cases results unsuccessful.
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• Second, transfusion may imply some safety concerns. In
fact, an observational study showed that platelet transfu-
sion aimed to reach counts greater than 50  109/L to
maintain anticoagulation, was not only unable to reduce
the hemorrhagic risk but was associated with frequent
transfusion-related adverse effects.72
By contrast, some studies assessed other alternatives:
• A recent observational study performed at the Memorial
Sloan Kettering Cancer Center validated a dynamic strat-
egy of enoxaparin dose reduction with the purpose of
avoiding platelet transfusion. Such practice could be
implemented at anyVTE period, even in thefirst month.73
In this study, therapeutic doses of enoxaparin were admi-
nistered in case of platelet counts greater than 50  109/L,
while half-dosewas usedwith platelet counts between 25
and 50  109/L. Anticoagulant treatment was withheld if
counts were less than 25  109/L. An IVCF was placed in
21 out of the 99 patients who participated in the study.
• Likewise, an intermediate strategy has also been pro-
posed, which encourages platelet transfusion albeit
with a lower threshold, 20  109/L.71
In the very recent update of the ISTH guidelines, the
experts suggest a dose modification strategy using 50% or
prophylactic-dose LMWH for patients with platelet count of
25 to 50  109/L and acute CATwith lower risk of thrombus
progression (i.e., distal DVT, incidental subsegmental PE, or
CVC-DVT). In case of higher risk of thrombus progression,
platelet transfusion to maintain a platelet count over 40 to
50  109/L and use of full-dose LMWH are recommended.74
Finally, in a novel study from the RIETE registry (R.
Lecumberri, MD, PhD, May 2018, unpublished data), the use
of lower doses of LMWH in patients with acute CAT and severe
thrombocytopenia seemed to be effective and safe, leading to
lowearly ratesofmajorbleedingandrecurrentVTE,verycloseto
those observed in cancer patients with normal platelet counts,
although cancer-related mortality was significantly increased.
Suggestions
• In case of mild thrombocytopenia (platelet counts
50  109/L), keeping anticoagulant treatment at full
therapeutic doses is suggested.
• In case of thrombocytopenia with counts lower than
50  109/L but higher than 20  109/L, a 50% reduction
in the LMWH dose is suggested.
• In case of thrombocytopenia with counts equal or lower
than 20  109/L:
– If VTEwas diagnosedmore than 30 days ago, temporary
interruption of anticoagulant treatment is suggested.
– If VTE diagnosis was less than 30 days ago (acute VTE),
platelet transfusion aimed to keep counts above
20  109/L, and anticoagulation using intermediate
LMWH doses, is suggested.
• In the acute phase of VTE, placement of an IVCF can be
considered in case of platelet counts equal or lower than
20  109/L or in patients with low cardiopulmonary
reserve and counts ranging between 20 and 50  109/L,
especially if thrombocytopenia is anticipated to continue
for more than 5 to 7 days.
Question 10: In Patients with CAT Requiring
Anticoagulant Treatment and Who Were under
Antiplatelet Therapy, When Should the Latter Be
Maintained?
Background
Evidence on the need of maintaining or stopping antiplatelet
therapy in patients with CAT is lacking. However, some data
from atrial fibrillation (AF) and coronary artery disease
patients may be useful:
• The use of VKA to treat a VTE event in patientswith cancer
is associated with a 3- to 6-fold higher hemorrhagic risk
than that observed in patients without cancer.75
• Many randomized clinical trials have shown that LMWH is
safe and effective in acute coronary syndrome (ACS)
without ST elevation.76
• In AF patients who have stable coronary disease and for
whom anticoagulation is indicated, oral anticoagulation
therapy (mainly VKA) protects against ischemic stroke
and coronary events.77
• In AF patients who have stable coronary disease, the
combination of VKA and acetylsalicylic acid (ASA), com-
paredwith VKA alone, does not reduce the riskof stroke or
acute myocardial infarction but increases the risk of
severe bleeding by 1.5- to 2-fold.78
• Adding clopidogrel to the combination of warfarin and
ASA in patients who have suffered an ACS markedly
increases the rate of severe hemorrhage (4.6% at
30 days and 10.3% at 6–12 months).79
• InpatientstreatedforanACSandinthosewhohaveundergone
the placement of a coronary stent, the triple therapy consist-
ingoforal anticoagulation, clopidogrel, andaspirin seems to
be justified during a limited period.80 In patients with high
bleeding risk, the triple therapy might be limited to the
first monthafter theACS,andbefollowedbydoubletherapy
(VKA together with ASA or clopidogrel) for up to 1 year.
On the other hand, in the field of myeloproliferative
neoplasms, both arterial and venous thrombotic complica-
tions are frequent. ASA is frequently used as primary pro-
phylaxis or as secondary prophylaxis after an arterial event.
In spite of the benefit of aspirin in reducing thrombotic
complications, this benefit is probably overweighed by the
increase of bleeding risk due to the association of ASA plus
anticoagulation in comparison to anticoagulants alone.81–83
Suggestions
• Since anticoagulation at therapeutic doses is effective to
prevent coronary disease progression, and the addition of
antiplatelet drugs increases the hemorrhagic risk, the
indication of combined antiplatelet plus anticoagulant
treatment for CAT should be limited to exceptional situa-
tions involving a very high risk of coronary event.
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• Maintenance of antiplatelet therapy in patients who are
going to start anticoagulant therapy for CAT is justified in
case of recent (<1 year) ACS event or placement of a
coronary stent.
• In patients with CAT carrying stents in other vascular beds,
maintenance of antiplatelet treatment while on anticoagu-
lant therapy should be decided in a case-by-case basis.
Question 11: In Cancer Patients Treated with LMWH,
When Should Anti-factor Xa Activity Be Monitored?
Background
In the pivotal studies comparing LMWH versus VKA in CAT,
body weight–adjusted LMWH doses were used.55,84,85 Data
fromthosestudies ruledout a significant LMWHaccumulation
over time, since anti-factor Xa activity (anti-Xa) remained
stable.86 Therefore, in spite of thehigher riskof recurrence and
bleeding in cancer patients, there is no evidence to support
routine monitoring of anti-Xa activity to adjust LMWH dose.
• However, patientswith severe renal failure (creatinine clear-
ance <30mL/min) were excluded from those clinical trials.
Clinical practice guidelines suggestmonitoring anti-Xa activ-
ity when using therapeutic doses of LMWH in patients with
severe renal impairment, and also consider initial dose
reduction when using enoxaparin or bemiparin.87
• Due to variations in drug distribution, the suitability of
monitoring anti-Xa activity in patientswith extremebody
weight and pregnant women has also been suggested.87
• Additionally, monitoring anti-Xa activity in high bleeding
risk scenarios, for instance, patients with thrombocyto-
penia, has also been proposed.88 However, pharmacoki-
netics of LMWH would not be influenced under these
conditions. The same applies to patients who have suf-
fered a recurrent event in spite of treatment with LMWH.
An empirical dose increase is recommended, although
monitoring of anti-Xa activity might help in optimizing
treatment.
• Importantly, the association between anti-Xa activity and
either clinical efficacy or bleeding risk has not been
undoubtedly demonstrated.89 Therefore, in the earlier
two mentioned scenarios, decisions on LMWH dose
should not rely on anti-Xa assessment only.
Finally, the goals of anti-Xa activity for the different
LMWH molecules have been retrospectively established.
When LMWH is administered in a once-daily regimen, the
goal of peak anti-Xa activity is generally around 1 IU/mL.
Suggestions
• In patients with CAT, routine monitoring of anti-Xa activ-
ity is not required to adjust LMWH dose.
• Renal function should be assessed in patients receiving
LMWH at therapeutic doses. If creatinine clearance is less
than 30mL/min, LMWH dose adjustment according to
peak anti-Xa activity is suggested (sample withdrawn
4 hours after subcutaneous LMWH administration).
Repeated monitoring over time is advisable.
• Monitoring anti-Xa activity in patientswith extremebody
weight (after several days of treatment) and in pregnant
women (once per trimester) is suggested.
• Monitoring anti-Xa in patients with thrombocytopenia or
with other hemorrhagic risk factors is not suggested. The
LMWH dose should not rely on this variable.
• Monitoring anti-Xa activity is not suggested for prophy-
lactic doses of LMWH.
Question 12: Should Thrombophilia Study Be
Performed in Patients with CAT?
Background
Thrombophilia is mainly characterized by VTE at early ages
(40–50 years), unprovoked events, or triggered by weak
stimuli, recurrences, thrombosis at unusual sites, or strong
family history of VTE.90 The term “hereditary thrombophi-
lia” usually includes deficiency of natural anticoagulants
(antithrombin, protein C, protein S), factor V Leiden, and
prothrombin G20210A mutation, while lupus anticoagulant
or antiphospholipid antibodies are considered acquired
thrombophilia.90 The following points summarize some
reasoning that does not support the search for these
abnormalities in the context of CAT, since the clinical
usefulness and benefits of such practice are rather limited
or nonexistent.
• VTE management is generally guided by the clinical fea-
tures of the event. Thrombophilic abnormalities do not
usually change clinical decisions, except for antiphospho-
lipid syndrome and antithrombin deficiency, associated
with high recurrence risk, which may favor indefinite
anticoagulant treatment. In fact, the main clinical practice
guidelines on VTE management do not consider that
thrombophilic abnormalities are relevant for initial treat-
ment or duration of therapy.43,91,92Moreover, the selection
of patients who would benefit from thrombophilia assess-
ment is under discussion, although identification of throm-
bophilic abnormalities could influence decisions on
anticoagulant treatment duration in patients with recur-
rent VTE or with strong family history.93–96
• Patients with cancer exhibit a higher VTE risk. Although a
thrombophilic factor could further increase the risk, VTE
management in cancer patients is not influenced by the
existence of associated thrombophilia: initial recom-
mended treatment is similar to that used in nonthrom-
bophilic cancer patients with VTE, and duration of
therapy is mainly influenced by persistence of cancer
and/or active oncologic treatment.42–44,91
In sum, the existing literature does not provide evidence
to justify, at first, a study of thrombophilia in patients with
CAT, and guidelines do not recommend to perform it on a
routine basis.
Suggestions
• The routine search for thrombophilia in patients with CAT
is not recommended.
TH Open Vol. 2 No. 4/2018




















































VTE is an important and potentially avoidable cause of
morbimortality in cancer patients that influences prognosis
and quality of life. The variety and complexity of clinical
scenarios in this setting explains why many therapeutic
decisions remain controversial. This consensus was the
result of the interest shown by three scientific societies—
namely, SETH, SEOM, and SEMI—in CAT. The applied meth-
odology allowed a multidisciplinary approach to each ques-
tion, as well as validation of the final statements by a solid
critical mass, which is particularly important in the absence
of strong scientific evidence. The suggestions presented
herein may constitute the bases for clinical decisions in
specific complex circumstances, until these can be made
leaning on reliable scientific evidence.
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